Oncology data evolves and emerges at a rapid pace leading to a proliferation of new actionable mutations, therapeutic targets, new therapies, and changes in treatment sequencing. The Keeping Pace in Oncology CME series has been developed to synthesize the latest data from clinical trials to help community oncologists keep pace with the rapid changes and best practices for integrating advances into clinical practice. Educational modules feature conversations with leading experts to explore clinical insights and perspectives on patient-centered treatment.
State of the Union: A Targeted Approach in First-Line Treatment of CLL/SLL
State of the Union: A Targeted Approach in First-Line Treatment of CLL/SLL
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022
Keeping Pace in Hematologic Malignancies: Newly Diagnosed Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Newly Diagnosed Multiple Myeloma
Tackling Adverse Events Associated with Disruption of B-Cell Receptor Signaling: A Multispecialty Approach
Tackling Adverse Events Associated with Disruption of B-Cell Receptor Signaling: A Multispecialty Approach
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
Managing and Monitoring MDS: MDS-Related Effects and Progression to AML
Managing and Monitoring MDS: MDS-Related Effects and Progression to AML
A New Light in Higher-Risk MDS: Emerging Treatment Options
A New Light in Higher-Risk MDS: Emerging Treatment Options
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Stratifying MDS
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Stratifying MDS
Keeping Pace in Lung Cancer: Improving Outcomes for Patients with RET-Positive NSCLC
Keeping Pace in Lung Cancer: Improving Outcomes for Patients with RET-Positive NSCLC
Keeping Pace in Bladder Cancers: All About Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma
Keeping Pace in Bladder Cancers: All About Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma
Keeping Pace in Lung Cancer: Applying the Right Therapy to the Right Patient in RET-Positive NSCLC
Keeping Pace in Lung Cancer: Applying the Right Therapy to the Right Patient in RET-Positive NSCLC
The Role of HER3 Expression in Advanced Solid Tumors
The Role of HER3 Expression in Advanced Solid Tumors